



Immedica Strengthens Focus on Rare Diseases with New Therapeutic Area

Stockholm, April 10, 2025 – Immedica continues to expand its presence in the rare disease space by introducing a new Therapeutic Area (TA) and refining its existing structure. This strategic development follows the recently announced acquisition of Marinus Pharmaceuticals, further reinforcing Immedica's commitment to delivering innovative treatments to patients with rare conditions.

The newly established Therapeutic Area, RARE Neurology, will focus on addressing the needs of patients with rare neurological diseases. This addition strengthens Immedica's portfolio and aligns with the company's mission to bring life-changing therapies to underserved patient populations.

In parallel, Immedica is refining its existing rare disease Therapeutic Areas to reflect its strong focus on the rare disease community:

- RARE Metabolic (formerly Genetic & Metabolic Diseases)
- RARE Hematology & Oncology (formerly Hematology & Oncology)

By integrating "RARE" into each TA, Immedica underscores its unwavering commitment to patients with rare diseases. Additionally, Specialty Care remains a key part of the company's therapeutic focus.

"All our Therapeutic Areas hold equal importance, and our goal is to maximize their potential. This refined structure enables us to strengthen our performance and continue delivering meaningful impact for people living with rare diseases," said Anders Edvell, CEO at Immedica Pharma.

With this enhanced focus, Immedica is well-positioned to further drive innovation and improve access to treatments for patients across its expanded rare disease portfolio.

About Immedica

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology and specialty care. Immedica was founded in 2018 and employs today around 140 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo.

For more information visit www.immedica.com.

Immedica contact:

Linda Holmström
Head of Communication

linda.holmstrom@immedica.com

+ 46 708 73 40 95

Immedica Pharma AB

Solnavägen 3H

SE-113 63 Stockholm